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Background: The identification of potential tumor markers will help improve therapeutic planning and patient
management. Thrombomodulin (TM) is a sensitive urothelial marker. TM was reported to be one of the
endogenous anti-metastatic factors and has diagnostic and prognostic values for the progression of carcinoma. In
the present study, we examine the role of TM in bladder cancer.
Methods: We studied the role of TM in tumor behavior and related signaling pathways in vitro using the human
bladder cancer cell lines HT1376, HT1197, J82 and T24, and in vivo using animal models. We also selected clinical
specimens from 100 patients with bladder cancer for immunohistochemical staining to evaluate the predictive
capacity of TM in tumor invasiveness.
Results: The data revealed that positive immunoreactivity for TM was inversely correlated with clinical stage and
DNA methyltransferase 1 immunoreactivity. Decreased TM expression could predict the aggressive tumor growth
and advanced clinical stage in bladder cancer. When TM was inhibited, tumor growth rate and invasion ability were
augmented in vitro and in vivo. The underlying changes included increased cell proliferation, enhanced
epithelial-mesenchymal transition (EMT) and angiogenesis. Moreover, inhibition of NF-κB activation significantly
increased TM expression and attenuated tumor aggressiveness in bladder cancer.
Conclusions: TM plays an important role in bladder cancer tumor aggressiveness in vitro and in vivo and is a
clinically significant predictor that may represent a suitable therapeutic target for bladder cancer.
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Urinary bladder cancer represents a spectrum of neo-
plasms, including non-muscle invasive, muscle invasive,
and metastatic lesions. Approximately 70% of patients
present with non-muscle invasive tumors, while the re-
maining 30% present with muscle-invasive bladder can-
cers. Despite good prognosis for patients with superficial
disease, superficial bladder cancer has a very high rate of
recurrence after treatment [1]. Of these recurrent tumors,
10–30% show progression in grade and stage [2]. Unlike
other urological cancers, bladder cancer lacks clinically
useful biomarkers for predicting disease stage and clinical
outcome [3]. Therefore, molecular markers that can be* Correspondence: miaofen@adm.cgmh.org.tw
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a tumor and its response to specific therapies are required.
Thrombomodulin (TM), a type 1 transmembrane glyco-
protein, is an anticoagulant factor [4,5] that mediates
hemostatic function and regulates multiple functions im-
portant in inflammation and tumor promotion [6-9]. A
potential role for TM in tumor biology was further sug-
gested by studies showing that TM expression in tumor
tissues correlated with a less advanced stage at diagnosis
and a better prognosis for multiple cancers [6,10-12].
Anticoagulation, anti-inflammation, adhesion and prolifer-
ation have all been suggested as mechanisms mediating
the effects of TM in tumors. Although TM expression
in tumor cells has been suggested to limit the invasive
potential and proliferation of tumor cells in certain
types of cancers, its role in bladder cancer remains to
be elucidated.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a substantial number of cancers [13,14], and data from
animal and human studies strongly support the hypoth-
esis that chronic inflammation plays a role in bladder
carcinogenesis [15,16]. TM has been considered as a sen-
sitive, but nonspecific, marker of urothelial carcinoma
[17,18]. Moreover, the anti-inflammatory role of TM has
been clearly demonstrated in vivo [9,19,20], in which it
modified the inflammatory response, maintained the in-
tegrity of cell-cell interactions, and reduced matrix deg-
radation. Thus, TM might play a role in bladder cancer,
even though the mechanisms underlying TM’s role remain
unclear. Several factors are implicated in regulation of
TM expression including DNA methylation and nuclear
factor-Kappa B (NF-κB) [21,22]. We have previously re-
ported that DNA methyltransferase1 (DNMT1) indicates
more aggressive tumor growth and resistance to treatment
in bladder cancer [23], and the activation of DNMT1 is
enhanced by inflammatory cytokines [24]. Moreover,
NF-κB is widely-recognized as a key regulator of the in-
flammatory responses, and plays an important role in
various types of human cancers including bladder can-
cer [25-27]. Therefore, we proposed the inhibition of
TM by NF-κB activation and DNMT1 might mediate in
part the aggressive bladder tumor behavior.
Herein it is shown that decreased TM expression could
predict the aggressive tumor growth and advanced clinical
stage in bladder cancer. In addition, the link between TM
signaling, the activation of NF-κB and DNMT1 in bladder
cancer was demonstrated. The study highlight a potential
role for TM as a molecular predictor and therapeutic
target for bladder urothelial carcinoma.
Methods
Patient characteristics for immunohistochemical
(IHC) staining
The Institutional Review Board of our Hospital approved
the present study. Informed written consent was obtained
from patients for the acquisition and storage of medical in-
formation and tissue specimens. A total of 100 patients
with bladder TCC, 60 with muscle-invasive tumors and 40
with non-muscle-invasive tumors, were enrolled in the
study. Formalin-fixed, paraffin-embedded tissues obtained
by transurethral resection in the diagnosis were cut into 5-
μm sections and mounted on slides for IHC staining. For
histological evaluation of TM immunoreactivity, the stain-
ing was scored independently by two observers blinded to
the clinical outcome; discordant scores were reviewed, and
a consensus was reached. Positive IHC scoring was defined
as > 10% positive tumor cells.
Cell culture and reagents
Four human bladder cancer cell lines, HT1376, HT1197,
T24 and J82, were obtained from the American TypeCulture Collection (ATCC). We maintained the bladder
cancer cell lines in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum. The TM si-
lencing vector (the TM shRNA lentiviral transduction
particles with puromycin resistance) and control vector
(consisting of a non-effective scrambled shRNA cassette)
were purchased from Santa Cruz Biotechnologies (Santa
Cruz, CA, USA). Stable TM-silenced cancer cells were
generated by transfecting bladder cancer cells with the
TM silencing vector and selected by culturing in medium
containing puromycin for 4 weeks. The DNA methyltrans-
ferase (DMNT) inhibitor 5-aza-2′-deoxycytidine (5-AZDC)
and caffeic acid phenethyl ester (CAPE), a specific inhibitor
of NF-κB, were obtained from Sigma (St. Louis, MO, USA).
Ectopic and orthotopic tumor xenograft model
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals as promulgated by the Institutes of
Laboratory Animal Resources, National Research Council,
U.S.A. The protocol was approved by the Committee on
the Ethics of Animal Experiments of our Hospital. Eight-
week-old female athymic nude mice were used as the xeno-
graft tumor implantation model. In the ectopic tumor im-
plantation model, 1 × 106 tumor cells were subcutaneously
implanted by injection into the dorsal gluteal region (five
animals/group). Tumor size was measured every 3 days
after implantation (day 0). The tumor volume was calcu-
lated assuming an ellipsoid shape. In the orthotopic tumor
implantation model, we performed intravesicular instilla-
tion of cancer cells as described previously (five animals/
group). The extent of orthotopic tumor invasion was mea-
sured after implantation at the indicated times. The effect
of CAPE treatment was also investigated in vivo. In the
treatment group, mice received intraperitoneal injection of
4 mg/kg CAPE solubilized in a saline vehicle solution
containing 20% dimethylsulfoxide (DMSO) 3 times per
week for 2 weeks starting on day 3. CAPE-treated mice
were compared with the control group mice, which were
treated with vehicle only.
Cell migration and cell invasion assays
Cell invasion capacity was determined using the Cell In-
vasion Assay (Trevigen, Gaithersburg, MD, USA). The
top chambers were pre-coated with basement membrane
extract derived from the Engelbreth-Holm-Swarm (EHS)
tumor provided in the kit. After incubation for 24 h, the
number of cells in the bottom chamber was determined
by measuring the fluorescent anion calcein released from
the intracellular calcein acetoxymethylester. To validate
experiments on cell migration, scratch assays were per-
formed by drawing a 2-mm wide scratch across each cell
layer using a pipette tip. The plates were photographed
at the times indicated.
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Cells were seeded onto glass coverslips at 5 × 104 cells/ml
in 6-well plates for IF staining with or without treatment.
After treatment at the specified times, cells were fixed with
2% paraformaldehyde for 5 min and washed in phosphate
buffered saline (PBS) with Tween-20 (PBST). The slides
were incubated for 1 h at room temperature with antibodies
against TM, E-cadherin and cleaved caspase 3, followed by
incubation with a FITC-conjugated secondary antibody for
1 h and counterstained with DAPI to visualize nuclei.
Real-time reverse transcription-polymerase chain
reaction (RT-PCR)
Real-time RT-PCR was performed on RNA extracted from
cell cultures. The primer sequences were as follows: (for-
ward and reverse, respectively) 5′-TAACGAAGACACA
GACTGCGA TT-3′ and 5′-CTAGCCCACGAGGTCAA
GGT-3′ for TM. A β-actin primer set was used as a load-
ing control. The optimized PCR was performed on an
iCycler iQ Multicolor Real-Time PCR detection system.Figure 1 Levels of TM in bladder cancer cell lines. (a) Levels of TM wer
and Western blot analyses. For real-time RT-PCR analysis, the y-axis represe
expression in HT1197 cancer cells. (b) The invasive capacity of bladder cance
slides are shown. The y-axis represents the ratio of invading cells detected in
Data are expressed as the mean of three separate experiments ± SD; *P < 0.0Significant fluorescent PCR signals from carcinoma tis-
sue were normalized relative to the mean value of sig-
nals obtained from control samples.
Statistical analysis
Data were presented as means ± standard error of the
mean (SEM) in triplicate for each experiment, and the
entire set of experiments was replicated at least twice.
Significant differences between groups were assessed using
the log-rank test. Significant differences between samples
were determined using the Student’s t-test. All statistical
tests were two-sided, with P < 0.05 indicating significance.
Results
Role of TM in tumor invasion and epithelial-mesenchymal
transition (EMT)
Differential expression of TM was observed in the four
types of bladder cancer cells (Figure 1a), and expression of
TM was negatively correlated with cell invasion in vitro
(Figure 1b). To determine whether altering TM expressione examined in HT1197, HT1376, T24 and J82 cell lines using RT-PCR
nts the ratio of TM expression in four cancer cell lines relative to the
r cells was evaluated by invasion assays. The results from representative
four bladder cancer cell lines normalized to that in HT1197 cancer cells.
5. (BA1 = HT1197; BA2 = HT1376; BA3 = T24; BA4 = J82).
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HT1376 bladder cancer cells, which have high TM expres-
sion levels, were transfected with a TM silencing or con-
trol vector. As shown in Figure 2a, the TM silencing
vector significantly inhibited TM expression in both cell
lines and augmented bladder cancer migration in vitro
(Figure 2b). An orthotopic tumor implantation technique
was used to examine the effect of TM silencing on tumor
cell invasion in vivo. Mice received intravesical instillation
of each bladder cancer cell line. After 21 days, intravesical
tumors developed in 60% of mice instilled with HT1197
cells, in 93% with HT1197 cells + TM silencing vector, in
50% with HT1376 cells, and in 95% with HT1376 cells +
TM silencing vector. As shown in Figure 2c, the TM silen-
cing vector increased the rate of tumor implantation in
the bladder and was associated with a larger tumor size.Figure 2 Role of TM in tumor invasiveness. (a) IF and Western blot ana
expression in HT1197 and HT1376 cells. Representative micrographs are sh
by the TM silencing vector compared with the control vector (CV). (b) The
vector or CV was evaluated by migration scratch assays. The results from re
cancer cells was evaluated using murine orthotopic tumor implantation. Th
represents the ratio of mice presenting intravesicular tumors normalized to
increased the rate of tumor implantation in the bladder and was associated
separate experiments ± SD; * P < 0.05.EMT is a key event in invasiveness, and we deter-
mined whether it is the underlying mechanism respon-
sible for the effects of TM on bladder cancer. Treatment
with a TM silencing vector promoted EMT in bladder
cancer cells, as determined by altered expression of
E-cadherin and Snail (Figure 3a–b). Data from Western
blots in vitro and IHC in vivo further revealed that the
TM silencing vector resulted in higher expression of
vascular endothelial growth factor (VEGF) and matrix
metalloproteinase (MMP)-9 and increased angiogenesis
(Figure 3b–c).
Role of TM in tumor growth and related mechanisms
By counting the viable cell numbers over 6 days, we de-
termined that the TM silencing vector significantly in-
creased the proliferation rate of HT1197 and HT1376lyses demonstrated the effects of the TM silencing vector on TM
own (DAPI = blue; TM = green). TM levels were significantly decreased
invasive capacity of bladder cancer cells expressing the TM silencing
presentative slides are shown. (c) The invasive capacity of bladder
e representative slides and quantitative data are shown. The y-axis
that received orthotopic tumor implantation. The TM silencing vector
with larger tumor size. Data are expressed as the mean of three
Figure 3 Role of TM in EMT changes. (a) Changes in E-cadherin expression were evaluated, and the representative micrographs are shown
(DAPI = blue; E-cadherin = green). (b) Change in EMT-associated proteins in cells transfected with the TM silencing (TM−) or control vectors (CV).
(c) Changes in VEGF, MMP-9, and CD31 expression in tumor xenografts were evaluated by IHC staining. The results from representative slides are shown.
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observed that inhibition of TM resulted in an increased
rate of tumor growth (Figure 4b). The data demonstrate
that the TM silencing vector significantly augmented the
growth rate of HT1197 and HT1376 bladder cancer cell
lines. Tumor cells can be eliminated by apoptosis, necro-
sis, mitotic catastrophe, and premature senescence. There-
fore, changes in the rates of cell death, apoptosis and
autophagy were measured. The cell death rate decreased
from 11.3 ± 1.4% to 4.3 ± 1.2% in HT1197 cells and from
13.7 ± 1.2% to 7.2 ± 1.3% in HT1376 cells after transfecting
with the TM silencing vector (Figure 4c). The TM silen-
cing vector noticeably decreased the rate of apoptosis, as
determined by cleaved caspase 3 staining (Figure 4d).
Furthermore, results from IF and Western blots using
an antibody against LC3 demonstrated that the TM si-
lencing vector resulted in a significant decrease in cell
autophagy in HT1197 and HT1376 cells (Figure 4e).
Moreover, Western blots showed that the rapid tumor
growth induced by the TM silencing vector was associ-
ated with increased anti-apoptotic Bcl-2 and decreased
p53 expression (Figure 4f ).Level of TM in bladder cancer tissue
IHC staining of bladder tissue specimens from bladder
cancer patients demonstrated that positive expression
of TM inversely correlated with tumor invasion depth
(Figure 5a). Positive staining for TM was evident in 40%
(24/60) of T2-T4 bladder cancer tissues and 75% (30/40) of
early stage tumors (CIS, Ta, or T1). We previously reported
that higher DNMT1 levels were associated with aggressive
tumor behavior and higher clinical stage in bladder cancers
[22]. Thus, in this study, we further investigated the
correlation between DNMT1 and TM expression. As
shown in Figure 5b, there was a negative correlation
between the expression of TM and DNMT1 in bladder
cancer specimens. This result correlated with mRNA
and protein levels in vitro demonstrating that inhib-
ition of DNMT1 resulted in increased TM expression
(Figure 5c).
Effect of TM by CAPE on bladder cancer
NF-κB is a critical mediator of TM expression [21] and
transcription of inflammatory cytokines [28], while CAPE
significantly attenuated NF-κB activity and suppressed the
Figure 4 Role of TM in tumor growth. (a) Effects of the TM silencing vector on the proliferation rates of HT1197 and HT1376 cancer cells. The
number of viable cells was counted after incubation for 2, 4, and 6 days. The y-axis represents the viable cell number. (b) Effects of TM inhibition
on xenograft tumor growth. Each point represents the mean of three separate experiments ± SD; *, P < 0.05. Expression of TM was also evaluated
by immunohistochemical staining of xenografts. Representative slides are shown at × 400 magnification. (c) Flow cytometry using annexin V-propidium
iodide (PI) staining for cell death rates in cells transfected with the TM silencing vector or control vector (CV). (d) Effect of TM silencing vector
on apoptosis demonstrated by IF analysis. The results from representative slides are shown (DAPI = blue; cleaved caspase 3 = green). (e) Effect
of TM silencing vector on autophagy demonstrated by IF analysis. The results from representative slides are shown (DAPI = blue; LC3 = green).
The level of LC3 II was also examined by Western blot analysis in cells transfected with the CV or the TM silencing vector (TM−). (f) Effects of the
TM silencing vector on the expression of apoptosis- and cell aging-related proteins evaluated by Western blot. Data points represent the mean
of three separate experiments ± SD. *, P < 0.05.
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[29,30]. In the present study, we examined the effects of
CAPE on TM expression and tumor aggressiveness of
bladder cancer cells. CAPE significantly increased TM
expression, which was associated with attenuated NF-κB
activation (Figure 6a–b). The viability of bladder cancer
cells after exposure to CAPE for 48 h was measured by
absolute cell number counts and using a xenograft tumor
growth model (Figure 6c–d), and CAPE was determined
to decrease tumor growth in vitro and in vivo. We further
examined whether CAPE attenuated the invasive capacity
of bladder cancer cells, and found that it was suppressedby CAPE treatment. In addition to NF-κB activation, the
expression of TM and the related EMT changes were also
attenuated by CAPE. Moreover, intraperitoneal injection
of 4 mg/kg CAPE significantly reduced the incidence of
developing intravesical tumors (Figure 6f).
Discussion
TM, an endothelial thrombin receptor, is a sensitive
urothelial marker expressed in 48–90% of urothelial car-
cinomas [17,18]. Although TM has been suggested pos-
sessing prognostic value in some cancers [6,10-12], the
predictive role of TM in bladder cancer requires further
Figure 5 Level of TM in bladder cancer. (a) Immunohistochemical staining with anti-TM antibody on human bladder cancer specimens.
Representative slides demonstrate that tumor cells showed TM-positive staining and that TM levels negatively correlated with clinical stage.
(b) TM levels were negatively correlated with DNMT1 expression in human bladder cancer specimens (P < 0.05). Representative slides of two
selected tumor specimens demonstrating staining for both TM and DNMT1 are shown. (c) The effect of DNMT1 inhibition on the level of TM
was examined by Western blots in cells transfected with the control vector (CV) and in cells transfected with the DNMT1 silencing vector
(DM−). (d) Effect of DNMT inhibition on the level of TM was examined by IF analysis. The results from representative slides are shown
(DAPI = blue; TM = green).
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role of TM in bladder cancer in the present study. The
data obtained from cellular experiments using bladder
cancer cell lines revealed that the expression of TM was
inversely correlated with the invasive ability. To investi-
gate whether TM was responsible for the less aggressive
behavior of bladder TCC, TM was suppressed in bladder
cancer cells by stable transfection with a silencing vector.
We found that the TM silencing vector significantly aug-
mented the invasive ability of cells detected in cellular inva-
sion assays and mouse orthotopic models. The molecular
and phenotypic changes involved in EMT appear to be
functionally relevant to the invasive characteristics of epi-
thelial tumors including bladder cancer [31,32]. At the mo-
lecular level, EMT is characterized by loss of E-cadherin, a
hallmark of EMT, and increased expression of invasion-
related factors [33]. This loss of E-cadherin was consistentlyobserved at sites of EMT in different human cancers and
with increased tumor cell invasiveness. We demonstrated
that silencing TM expression abolished the expression
of E-cadherin, associated with increased Snail, VEGF
and MMP-9 expressions. Snail has been reported to re-
presses transcription from the E-cadherin promoter and
promotes tumor cell metastasis [34,35]. In addition, in-
creased VEGF and MMP-9 expression correlated with
EMTchanges and poor prognosis of bladder cancer [36,37].
Angiogenesis is one of the mechanisms that promote tumor
progression, and it involves CD31-mediated endothelial
cell-cell interactions [38]. Our in vivo data revealed that
TM silencing augmented tumor invasiveness, which was
associated with increased MMP-9, CD31 and VEGF ex-
pression in tumors. On the basis of these findings, changes
in EMT might be responsible for reduced invasiveness in
TM-positive urothelial cancers.
Figure 6 Effects of CAPE on bladder cancer cells with lower TM expression. (a) The effect of CAPE treatment on the level of TM, NF-κB activation
and EMT-related changes was examined by Western blot using cells with lower TM expression in the presence or absence of 6 μg/ml CAPE for 48 h.
(b) Effect of CAPE treatment on the level of N-cadherin was examined by IF analysis in cells with lower TM expression in the presence or absence of
6 μg/ml CAPE for 48 h. The results from representative slides are shown (DAPI = blue; N-cadherin = green). (c) Effects of CAPE on the proliferation rates
of T24 and J82 cell lines were evaluated by viable cell counting and by colony formation in HT1197 and HT1376 cells with inhibited TM expression.
(d) Effects of CAPE treatment on xenograft tumor growth. (e) Effects of CAPE treatment on the invasive capacity of bladder cancer cells expressing the
TM silencing vector was evaluated by invasion assays. The results from representative slides are shown. (f) The invasive capacity of bladder cancer cells
with or without CAPE treatment was evaluated by murine orthotopic tumor implantation. Representative slides and quantitative data are shown. Data
are expressed as the mean of three separate experiments ± SD; * P < 0.05.
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silencing resulted in increased bladder tumor growth
in vitro and in vivo. Our in vitro experiments demonstrated
that inhibition of several types of cell death, including
apoptosis and cellular autophagy, were responsible for the
aggressive tumor growth induced by inhibiting TM. De-
creased cell death induced by the TM silencing vector was
associated with increased anti-apoptotic Bcl-1 expression
and decreased p53 expression.
Identification of potential molecular markers has im-
portant implications for the development and selection
of molecular targeting in cancer therapy. Our in vitro
and in vivo data revealed that loss of TM was associated
with more aggressive tumor growth. Accordingly, we pro-
posed that this loss of TM might be a clinically relevantcharacteristic linked to disease progression in bladder can-
cer. To test this hypothesis, we examined the expression of
TM in bladder cancer tissue using IHC and found that it
was expressed in 54% of these bladder cancer specimens.
Positive staining for TM was preferentially associated with
lower cancer stages relative to muscle-invasive bladder
TCC (40% of T2–T4 bladder cancer tissues vs. 75% in
Ta–T1). Our study established that the expression of
TM in muscle-invasive human bladder cancer is down-
regulated in comparison with superficial bladder cancer.
TM is reported to be expressed at the cell surface in
normal cells of epithelial origin, while TM staining was
not found in cells undergoing transformation into a ma-
lignant phenotype [39]. Silencing of the TM gene pro-
moter has been implicated in the down-regulation of TM
Figure 7 TM signaling pathway in bladder cancer.
Wu et al. BMC Cancer 2014, 14:375 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/375synthesis, [40]. Aberrant DNA methylation plays a key
role in carcinogenesis, leading to the epigenetic silencing
of the expression of tumor-suppressor genes. Moreover,
the expression of TM was restored after treatment with
DNMT inhibitor in certain types of cancer cells [22,41].
We previously reported [23] that DNMT1 could be a
significant clinical predictor of bladder cancer. Accord-
ingly, we further investigate the link between TM ex-
pression and DNMT1 in the present study. A negative
correlation between TM-positive samples and nuclear
staining for DNMT1 was found using IHC. We further
examined the relationship between TM and DNMT1 by
regulating DNMT1 expression. The mRNA and protein
levels revealed that inhibition of DNMT1 suppressed TM
expression. We therefore suggest that inhibition of TM
expression might be responsible for aggressive tumors in
DNMT1-positive bladder cancer.
Proinflammatory cytokines may be one of the mecha-
nisms underlying the notion that chronic inflammation
facilitates tumor progression [15]. Studies have identified
that DNMT1 expression may be directly altered by pro-
inflammatory cytokines such as IL-6. Many of the tran-
scriptional effects of inflammatory cytokines are mediated
by activation of NF-κB [25]. In cancer cells, NF-κB is often
activated aberrantly, promoting the invasion, metastasis,
and survival of these cells. Indeed, NF-κB overexpression
was associated with poor prognosis in various malignan-
cies, including bladder cancer [26,27]. The regulation of
TM by inflammatory mediators has been studied by sev-
eral groups, who concluded that NF-κB is a critical medi-
ator of TM expression by inflammatory cytokines [21].
Therefore, we propose that inhibition of NF–κB activation
may be a candidate strategy to regulate TM expression
and tumor promotion for bladder cancer. CAPE, an active
anti-inflammatory component of propolis, is a specific
inhibitor of NF-κB [42]. CAPE has been reported to sig-
nificantly inhibit the activation of NF-κB and attenuate
proinflammatory cytokine production in cancer cells
[29,30,43]. In the present study, we found that attenu-
ated NF-κB activation by CAPE treatment was associ-
ated with increased expression of TM in bladder cancer
cells. Our in vitro and in vivo data demonstrated that
CAPE obviously inhibited tumor growth and impaired
invasive ability associated with increased TM and atten-
uated NF-κB activation and EMT changes. By the data,
we suggested that regulation of TM expression is critical
in tumor aggressiveness and prognosis of bladder cancer.
We outlined the main signaling pathways that are thought
to link inflammation and TM signaling to the promotion
of bladder cancer (Figure 7).
Conclusion
Our in vitro and in vivo data indicate that TM plays an
important role in bladder cancer tumor aggressiveness.Moreover, TM is a clinically significant predictor that
might be partially responsible for aggressive tumors
in DNMT1-positive bladder cancer. CAPE could be a
promising therapeutic agent for bladder cancer that
inhibits NF-κB activation and reverses the response
induced by TM inhibition. Our study has established a
foundation for future studies on the role of TM in bladder
cancer progression and the therapeutic potential of TM in
bladder cancer treatment.
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